KdT Ventures | Activity | F4

Team Portfolio Raise Champions Essays

F4/KdT Ventures/Activity

KdT Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

3 investments· MAR 2026 – MAY 2026Show all

Investment

Participated in PHNX Materials' $6.5M seed financing to build domestic critical-materials supply from industrial waste.

PHNX Materials

PHNX Materials KdT Ventures

wsj.comMAY 8, 2026

MAY 8, 2026

Investment

Led $5M Series A for Index Biosystems, a food safety and biotech platform company using BioTag technology.

Index Biosystems

Index Biosystems KdT Ventures

indexbiosystems.com

Added recently

Investment

KdT Ventures participated in a US$12 million top-up financing for Reverb Therapeutics, a company developing a next-generation anti-PD-1 bispecific antibody (AMP01) leveraging its Amplify•R platform for cancer and autoimmune disease treatment.

Reverb Therapeutics

Reverb Therapeutics KdT Ventures

reverbtx.comMAR 20, 2026

MAR 20, 2026

Milestone

Portfolio company Montara Therapeutics announced first development candidate for BrainOnly platform.

Montara Therapeutics

Montara Therapeutics KdT Ventures

montaratx.comDEC 8, 2025

DEC 8, 2025

Investment

KdT Ventures participated in Skeletalis Bio's $8 million seed round (led by Pillar VC) to advance its bone-targeted small molecule candidate for osteoporosis treatment.

Skeletalis

Skeletalis KdT Ventures

skeletalis.bioNOV 17, 2025

NOV 17, 2025

Investment

KdT Ventures participated in Zag Bio's $80 million Series A financing (co-led by Polaris Partners and T1D Fund) to advance thymus-targeted medicines for autoimmune diseases, with a lead program in Type 1 diabetes (ZAG-101).

Zag Bio

Zag Bio KdT Ventures

zagbio.comOCT 28, 2025

OCT 28, 2025

3 exits· JAN 2025 – OCT 2025Show all

Exit

Portfolio company MapLight Therapeutics completed IPO in October 2025.

MapLight Therapeutics

MapLight Therapeutics KdT Ventures

pharmexec.comOCT 26, 2025

OCT 26, 2025

Exit

Portfolio company SeQure DX was acquired by MaxCyte in January 2025.

SeQure DX

SeQure DXKdT Ventures

pitchbook.comJAN 2025

JAN 2025

Exit

Portfolio company Tavros Therapeutics achieved acquisition.

Tavros Therapeutics

Tavros Therapeutics KdT Ventures

pitchbook.comJAN 2025

JAN 2025